| Characteristics | ACEI (n = 3131) | Thiazide (n = 1947) | Cardioselective β-blocker (n = 1029) | ARB (n = 533) | CCB (n = 529) | P* |
|---|---|---|---|---|---|---|
| Female sex, n (%) | 1442 (46.1) | 1248 (64.1) | 601 (58.4) | 275 (51.6) | 312 (59.0) | <.001 |
| Age at index (years) | 53.6 (13.0) | 52.6 (13.0) | 54.1 (14.4) | 55.2 (12.4) | 57.8 (14.7) | <.001 |
| BMI (kg/m2) | 30.9 (6.8) | 31.1 (7.3) | 28.9 (6.2) | 30.4 (6.1) | 29.7 (6.7) | <.001 |
| Index systolic BP (mm Hg) | 147.6 (15.0) | 149.3 (13.4) | 147.7 (15.4) | 147.8 (14.9) | 149.5 (15.7) | <0.001 |
| Index diastolic BP (mm Hg) | 90.1 (10.7) | 91.5 (10.1) | 90.1 (10.9) | 89.7 (10.4) | 89.4 (11.4) | <.001 |
| CKD, n (%) | 221 (7.1) | 127 (6.5) | 118 (11.5) | 52 (9.8) | 94 (17.8) | <.001 |
| Diabetes, n (%) | 789 (25.2) | 89 (4.6) | 75 (7.3) | 109 (20.5) | 29 (5.5) | <.001 |
| Hyperlipidemia, n (%) | 1177 (37.6) | 557 (28.6) | 296 (28.8) | 196 (36.8) | 155 (29.3) | <.001 |
| Hypertension, n (%) | 1902 (60.8) | 1335 (68.6) | 506 (49.2) | 258 (48.4) | 279 (52.7) | <.001 |
| Follow-up duration (months) | 6.5 (3.8) | 5.9 (3.9) | 6.3 (3.9) | 6.2 (3.8) | 6.4 (4.0) | <.001 |
| Number of clinic visits | 3.8 (3.2) | 3.9 (3.2) | 4.2 (4.0) | 3.6 (3.4) | 4.3 (3.8) | <.001 |
Data are mean (standard deviation) unless otherwise indicated.
↵* P values were from analysis of variance (ANOVA) or logistic regression and test the overall effect across the five therapeutic classes.
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; BMI, body mass index; BP, blood pressure; CCB, calcium channel blocker; CKD, chronic kidney disease; thiazide, thiazide and thiazide-like diuretics.